European Medicines Agency Changes Procedures for Orphan Drug Fees - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Changes Procedures for Orphan Drug Fees


The European Medicines Agency (EMA) has stopped requiring sponsors of orphan drugs to inform EMA of their intention to submit an application to be eligible for a fee reduction. This change is part of EMA’s effort to streamline the procedures for fee reductions and is effective immediately.

Drugs that have been granted orphan designation by the European Commission on the recommendation of the EMA’s Committee for Orphan Medicinal Products are eligible for fee reductions for a range of regulatory activities including pre-authorization activities such as protocol assistance, the application for marketing authorization, and inspections. EMA will no longer require additional information from the sponsor before submitting an application eligible for fee reduction for orphan drugs.
EMA has removed “Procedural Advice on Fee Reductions for Designated Orphan Medicinal Products” from the Agency’s website and the standard operating procedure on processing of fee reductions for designated orphan drug products (SOP/H/3048) is now obsolete.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here